All News
Guideline UpdateApril 11, 2026
Blood-Based Biomarker Revolution in Neurology: NfL, GFAP, and p-tau217
Alzheimer, MS, and ALS diagnosis and monitoring becoming possible with a simple blood test. NfL, GFAP, and p-tau217 entering clinical practice.
Blood-based biomarkers are revolutionizing neurological diagnosis. sNfL for MS activity and ALS progression, GFAP for progressive MS prediction, p-tau217 for Alzheimer's diagnosis with 95%+ accuracy. Simple blood tests replacing invasive CSF sampling and expensive PET imaging.
Source: Nature Reviews Neurology / JAMA / Lancet Neurology